poisar

Stocks · News reference

What's Going On With AbbVie Stock Friday?

Henry Khederian

AbbVie shares are edging higher Friday following Thursday's positive Phase 3 trial results for its menstrual migraine drug, atogepant.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ABBV
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s

    Eli Lilly's Immunology division generated $2.6 billion in revenues in H1 2026, up 9% year-over-year, representing 6.1% of total revenues. Led by Taltz, the portfolio is expanding through newer products like Ebglyss and Omvoh, plus strategic acquisitions of DICE, Morphic, and Merida to strengthen its pipeline across IBD, autoimmune diseases, and allergies. However, the company faces intense competition from established players and newer therapies.

    LLYNVSABBVJNJ
  3. Robert Izquierdo

    Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH

    Vanguard's VHT and State Street's XPH offer different approaches to healthcare investing. VHT provides broad sector exposure with lower costs (0.09% expense ratio) and higher dividend yield (1.5%), making it ideal for long-term investors. XPH focuses on pharmaceuticals with higher volatility but stronger 1-year returns (57.2% vs 29.3%), appealing to growth-oriented investors willing to accept greater risk.

    VHTXPHLLYJNJABBV